ES2076935T3 - Compuesto de pirazolopiridina y procedimientos para su preparacion. - Google Patents

Compuesto de pirazolopiridina y procedimientos para su preparacion.

Info

Publication number
ES2076935T3
ES2076935T3 ES88109331T ES88109331T ES2076935T3 ES 2076935 T3 ES2076935 T3 ES 2076935T3 ES 88109331 T ES88109331 T ES 88109331T ES 88109331 T ES88109331 T ES 88109331T ES 2076935 T3 ES2076935 T3 ES 2076935T3
Authority
ES
Spain
Prior art keywords
compound
preparation
pirazolopyridine
procedures
pirazilpiridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88109331T
Other languages
English (en)
Inventor
Youichi Shiokawa
Atsushi Akahane
Hirohito Katayama
Takafumi Mitsunaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878713908A external-priority patent/GB8713908D0/en
Priority claimed from GB878719724A external-priority patent/GB8719724D0/en
Priority claimed from GB878730330A external-priority patent/GB8730330D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2076935T3 publication Critical patent/ES2076935T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Position Input By Displaying (AREA)

Abstract

COMPUESTO DE PIRAZILPIRIDINA DE FORMULA (I) EN LA QUE LOS SUSTITUYENTES TIENEN EL SIGNIFICADO QUE SE DETALLA EN LA INVENCION Y UNA SAL SUYA FARMACEUTICAMENTE ACEPTABLE, PROCESOS PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN.
ES88109331T 1987-06-15 1988-06-11 Compuesto de pirazolopiridina y procedimientos para su preparacion. Expired - Lifetime ES2076935T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB878713908A GB8713908D0 (en) 1987-06-15 1987-06-15 Pyrazolopyridine compound
GB878719724A GB8719724D0 (en) 1987-08-20 1987-08-20 Pyrazolopyridine compound
GB878730330A GB8730330D0 (en) 1987-12-31 1987-12-31 Pyrazolopyridine compound & processes for preparation thereof

Publications (1)

Publication Number Publication Date
ES2076935T3 true ES2076935T3 (es) 1995-11-16

Family

ID=27263458

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88109331T Expired - Lifetime ES2076935T3 (es) 1987-06-15 1988-06-11 Compuesto de pirazolopiridina y procedimientos para su preparacion.

Country Status (16)

Country Link
US (6) US4925849A (es)
EP (1) EP0299209B1 (es)
JP (1) JP2674099B2 (es)
KR (1) KR890000483A (es)
CN (1) CN1031376A (es)
AT (1) ATE127801T1 (es)
AU (1) AU615913B2 (es)
DE (1) DE3854454T2 (es)
DK (1) DK323688A (es)
ES (1) ES2076935T3 (es)
FI (1) FI882813A7 (es)
GR (1) GR3017850T3 (es)
HU (1) HU200180B (es)
IL (1) IL86674A0 (es)
NO (1) NO168585C (es)
PT (1) PT87700B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US5338743A (en) * 1988-06-06 1994-08-16 Fujisawa Pharmaceutical Co., Ltd. New use of the adenosine antagonist
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
DE3942357A1 (de) * 1989-12-21 1991-06-27 Boehringer Mannheim Gmbh 3-aminopyrazolo-heterocyclen, deren verwendung zur bestimmung von wasserstoffperoxid, wasserstoffperoxid-bildenden systemen, peroxidase, peroxidatisch wirksamen substanzen oder von elektronenreichen aromatischen verbindungen, entsprechende bestimmungsverfahren und hierfuer geeignete mittel
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
ATE211384T1 (de) * 1991-01-29 2002-01-15 Fujisawa Pharmaceutical Co Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
GB9107513D0 (en) * 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
AU672773B2 (en) * 1992-01-29 1996-10-17 E.I. Du Pont De Nemours And Company Substituted phenylheterocyclic herbicides
US6358885B1 (en) 1992-01-29 2002-03-19 Mississippi State University Substituted phenylheterocyclic herbicides
US5670455A (en) * 1992-01-29 1997-09-23 E. I. Du Pont De Nemours And Company Substituted phenylheterocyclic herbicides
ATE161178T1 (de) * 1992-06-10 1998-01-15 Fujisawa Pharmaceutical Co Pyrazolpyridine für die behandlung der anämie
JPH07507796A (ja) * 1992-06-17 1995-08-31 ファルマシア・アンド・アップジョン・カンパニー 抗−アテローム性動脈硬化剤および抗−高コレステロール血症剤として有用なピリジノ−，ピロリジノ−，およびアゼピノ−置換オキシム類
US5541213A (en) * 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
CN1046724C (zh) * 1993-12-29 1999-11-24 藤泽药品工业株式会社 吡唑并吡啶化合物、含有它们的药物组合物、及其制法与用途
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
ATE220544T1 (de) * 1995-04-27 2002-08-15 Fujisawa Pharmaceutical Co Neue verwendung von pyrazolopyridinverbindungen
DE69731948D1 (de) * 1996-04-25 2005-01-20 Fujisawa Pharmaceutical Co Mittel zur vorbeugung und heilung ischämischer darmlesion und ileus
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
EP0972525A4 (en) * 1997-03-18 2000-11-29 Fujisawa Pharmaceutical Co PREVENTIVE AND HEALING AGENTS AGAINST HYPERPHOSPHATEMIA
ATE289295T1 (de) * 1997-04-22 2005-03-15 Euro Celtique Sa Die verwendung von durch carbozyklische und heterozyklische reste substituierte semicarbazonen und thiosemicarbazonen als natriumkanalblocker
EP1568690A1 (en) * 1997-04-22 2005-08-31 Euro-Celtique S.A. The use of carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones as sodium channel blockers
ATE281458T1 (de) * 1997-09-05 2004-11-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
AUPP672198A0 (en) * 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
ATE275148T1 (de) 1998-11-03 2004-09-15 Glaxo Group Ltd Pyrazolopyridin derivative als selektive cox-2 inhibitoren
WO2000052008A1 (en) 1999-02-27 2000-09-08 Glaxo Group Limited Pyrazolopyridines
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
FR2801308B1 (fr) 1999-11-19 2003-05-09 Oreal COMPOSITIONS DE TEINTURE DE FIBRES KERATINIQUES CONTENANT DE DES 3-AMINO PYRAZOLO-[1,(-a]-PYRIDINES, PROCEDE DE TEINTURE, NOUVELLES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
ES2245380T3 (es) * 2000-12-15 2006-01-01 Glaxo Group Limited Pirazolopiridinas.
EP1377573B1 (en) * 2000-12-15 2005-07-27 Glaxo Group Limited Pyrazolopyridine derivatives
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
US7153855B2 (en) * 2001-03-08 2006-12-26 Smithkline Beecham Corporation Pyrazolopyridinyl pyrimidine therapeutic compounds
EP1372643A1 (en) * 2001-03-30 2004-01-02 Smithkline Beecham Corporation Pyrazolopyridines, process for their preparation and use as therapeutic compounds
WO2002078701A1 (en) * 2001-03-30 2002-10-10 Smithkline Beecham Corporation Use of pyrazolopyridines as therapeutic compounds
JP4219171B2 (ja) * 2001-04-10 2009-02-04 スミスクライン ビーチャム コーポレーション 抗ウイルス性ピラゾロピリジン化合物
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
AU2002305143A1 (en) * 2001-04-27 2002-11-11 Smithkline Beecham Corporation Pyrazolo'1,5-a!pyridine derivatives
BR0209252A (pt) * 2001-04-27 2004-07-20 Eisai Co Ltd Pirazolo[1,5-a]piridinas e medicamentos contendo as mesmas
AUPR548601A0 (en) * 2001-06-06 2001-06-28 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazinecompound and pharmaceutical use thereof
KR20040018281A (ko) * 2001-06-21 2004-03-02 스미스클라인 비참 코포레이션 포진 바이러스 감염의 예방 및 치료를 위한 이미다조[1，２－α]피리딘 유도체
ES2286272T3 (es) * 2001-09-07 2007-12-01 Smithkline Beecham Corporation Pirizolo-piridinas para el tratamiento de infecciones por herpes.
US7244740B2 (en) * 2001-10-05 2007-07-17 Smithkline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
WO2003050120A1 (en) * 2001-12-11 2003-06-19 Smithkline Beecham Corporation Pyrazolo-pyridine derivatives as antiherpes agents
US20040021778A1 (en) * 2002-08-05 2004-02-05 Oldani Jerome L. Security system with remote access and control
WO2004033454A1 (en) * 2002-10-03 2004-04-22 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
US7176216B2 (en) * 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
AU2003275589B2 (en) * 2002-10-22 2009-05-28 Eisai R & D Management Co., Ltd. 7-phenyl pyrazolopyridine compounds
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP2007512337A (ja) 2003-11-21 2007-05-17 コンビナトアールエックス インコーポレーティッド 炎症性障害の治療のための方法および試薬
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
JP5352452B2 (ja) * 2006-06-06 2013-11-27 メディシノバ， インコーポレイテッド 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法
EP1939180A1 (en) * 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
US7536799B2 (en) * 2007-06-07 2009-05-26 Keson Industries Chalk line apparatus with strategically located chalk fill opening
MY152687A (en) * 2008-04-15 2014-10-31 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
EP2177218A1 (en) 2008-10-15 2010-04-21 Medizinische Universität Wien Regenerative therapy
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
JPWO2011043387A1 (ja) * 2009-10-08 2013-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
KR20150003766A (ko) 2012-04-26 2015-01-09 브리스톨-마이어스 스큅 컴퍼니 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피리다진 유도체
SG11201406759YA (en) 2012-04-26 2014-11-27 Bristol Myers Squibb Co Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
ES2640916T3 (es) 2012-04-26 2017-11-07 Bristol-Myers Squibb Company Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor 4 activados por proteasa (PAR4) para tratar agregación plaquetaria
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
SG11202112828SA (en) * 2019-06-04 2021-12-30 Hager Biosciences Llc Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
US11970499B1 (en) 2023-12-22 2024-04-30 King Faisal University Pyrazolo[1,5-c]pyrimidine compounds as CK2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5229318B2 (es) * 1972-03-30 1977-08-01
US4017597A (en) * 1974-10-30 1977-04-12 Monsanto Company Unitized solid phase immunoassay kit and method
US4097483A (en) * 1974-11-01 1978-06-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolo 1,5-a!pyridines
JPS5154583A (en) * 1974-11-01 1976-05-13 Kyorin Seiyaku Kk Shinkipirazoro * 1 55a * pirijinjudotaino seizoho
AU556031B2 (en) * 1982-06-16 1986-10-16 May And Baker Ltd. 3-(n,n-dimethylcarbamoyl)pyrazolo(1,5-alpha)-pyridine
JPS60248689A (ja) * 1984-05-24 1985-12-09 Mitsubishi Paper Mills Ltd ３−（３′−ピラゾロ〔１，５−ａ〕ピリジル）アクロレイン誘導体
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines

Also Published As

Publication number Publication date
US5102878A (en) 1992-04-07
EP0299209A2 (en) 1989-01-18
US4925849A (en) 1990-05-15
PT87700A (pt) 1988-07-01
US5087629A (en) 1992-02-11
NO168585C (no) 1992-03-11
CN1031376A (zh) 1989-03-01
EP0299209A3 (en) 1990-05-09
ATE127801T1 (de) 1995-09-15
NO168585B (no) 1991-12-02
PT87700B (pt) 1992-10-30
US5102869A (en) 1992-04-07
NO882608L (no) 1988-12-16
DE3854454T2 (de) 1996-02-15
JP2674099B2 (ja) 1997-11-05
JPS6445385A (en) 1989-02-17
US4994453A (en) 1991-02-19
FI882813A0 (fi) 1988-06-13
IL86674A0 (en) 1988-11-30
DK323688A (da) 1988-12-16
AU615913B2 (en) 1991-10-17
US5296490A (en) 1994-03-22
DE3854454D1 (de) 1995-10-19
AU1760288A (en) 1988-12-15
HUT47110A (en) 1989-01-30
KR890000483A (ko) 1989-03-14
FI882813A7 (fi) 1988-12-16
NO882608D0 (no) 1988-06-14
EP0299209B1 (en) 1995-09-13
DK323688D0 (da) 1988-06-14
HU200180B (en) 1990-04-28
GR3017850T3 (en) 1996-01-31

Similar Documents

Publication Publication Date Title
ES2084944T3 (es) Amidas terapeuticas.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
SE8602723L (sv) Tiazoler, deras framstellning och farmaceutiska kompositioner innehallande dem
SV1998000029A (es) Compuestos de pirazina ref. pg3186
ES2095432T3 (es) Derivados de 2,4-tiazolidin-diona, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
CO4940450A1 (es) Formulaciones farmaceuticas que contienen voriconazol
PA8452001A1 (es) Derivados de macrolidos c-4" sustituidos
ES2150489T3 (es) 1-amidinofenil-pirrolidonas, -piperidinonas, -azetinonas como inhibidores de la agregacion de plaquetas.
ES2157314T3 (es) Derivados triciclicos y su uso en productos farmaceuticos.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
ES2033985T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica.
MX9306311A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
PT97905A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados da cistina
NO960389L (no) Terapeutisk forbindelse - fettsyrekonjugater
ES2020171T3 (es) Eteres de 1-bencil-3-hidroximetilindazol con 2-hidroxiacidos alifaticos.
MX9204318A (es) Complejos de derivados de pleuromutilina para su preparacion y composiciones farmaceuticas que los contienen.
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2043863T3 (es) Procedimiento para preparar derivados de la 1,2,5,6-tetrahidropiridina.
ES2123499T3 (es) Metodos y composiciones para tratamiento de infecciones virales.
MX9306309A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
DK122191A (da) Benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 299209

Country of ref document: ES